U.S. markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.06 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,812.50
    -18.70 (-1.02%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1871
    -0.0025 (-0.21%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • GBP/USD

    1.3906
    -0.0051 (-0.37%)
     
  • USD/JPY

    109.6150
    +0.1540 (+0.14%)
     
  • BTC-USD

    41,754.66
    +1,791.78 (+4.48%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

New Coronavirus Testing Protocol Could Help Labs Keep Up With Rising Testing Demands as Delta Variant Spreads

·4 min read

WASHINGTON, July 21, 2021 /PRNewswire/ -- A first-of-its-kind study published today in AACC's Clinical Chemistry journal shows that a new protocol for coronavirus testing can increase clinical labs' testing capacity without sacrificing accuracy. This protocol could play a vital role in helping labs keep up with coronavirus testing demands as the Delta variant fuels a new increase in COVID-19 cases around the world.

(PRNewsfoto/AACC)
(PRNewsfoto/AACC)

View the full study here: https://doi.org/10.1093/clinchem/hvab132

Due to the highly transmissible Delta coronavirus variant, global COVID-19 cases have gone up 12% in the past week, and the average of new daily cases in the U.S. in particular has surged by 145% over the past two weeks. Making matters worse, vaccination coverage continues to lag. Many resource-limited countries are still struggling to secure coronavirus vaccines, while in the U.S., vaccine hesitancy is hindering efforts to achieve herd immunity. More than half of the U.S. population is unvaccinated and highly likely to remain that way, according to a recent poll published by Axios-Ipsos. All of this means that PCR coronavirus tests—the gold-standard for diagnosing COVID-19—will continue to play a central role in managing the pandemic for the foreseeable future. It also means that, with the pandemic in this new growth phase, the supply shortages that stymied testing for the first year of the pandemic must be prevented from reoccurring.

To support this goal, a team of researchers led by Lea Starita, PhD, and Christina Lockwood, PhD, of the University of Washington has developed a new, streamlined protocol for PCR coronavirus testing called SwabExpress. Typically, PCR coronavirus testing involves the extraction of viral genetic material from nasopharyngeal patient specimens transported in viral media. However, overreliance on this protocol throughout much of the pandemic contributed to a global shortage of extraction reagents, nasopharyngeal swabs, and viral media that hindered coronavirus testing even as recently as spring of 2021. SwabExpress, on the other hand, does not require viral media or extraction reagents, and also uses less invasive anterior nasal dry-swabs instead of nasopharyngeal swabs. All of this makes it ideal for averting future supply shortages and/or for use during periods of severe shortages.

In general, SwabExpress is much easier to perform than the standard PCR coronavirus testing protocol. After adopting SwabExpress, Starita and Lockwood's laboratory approximately doubled its capacity for coronavirus testing. Importantly, unlike other extraction-free methods for nasal swabs that have been developed, SwabExpress is also highly accurate. The researchers demonstrated that it has a sensitivity of 100% and a specificity of 99.4% when compared side-by-side with a traditional PCR protocol.

"Massive scaling and deployment of SARS-CoV-2 testing is essential to curtailing the COVID-19 pandemic, and will likely be necessary well into the future," said Starita and Lockwood. "The protocol evaluated here, including thousands of real-world, self-collected nasal swabs, would markedly simplify the workflow for RT-qPCR, the most widely deployed testing paradigm, by eliminating the need for viral transport media and RNA extraction. It may serve as a template for the simplification of PCR-based clinical laboratory tests, particularly in times of critical shortages during pandemics."

About AACC
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.

Clinical Chemistry (clinchem.org) is the leading international journal of laboratory medicine, featuring nearly 400 peer-reviewed studies every year that help patients get accurate diagnoses and essential care. This vital research is advancing areas of healthcare ranging from genetic testing and drug monitoring to pediatrics and appropriate test utilization.

Christine DeLong
AACC
Senior Manager, Communications & PR
(p) 202.835.8722
cdelong@aacc.org

Molly Polen
AACC
Senior Director, Communications & PR
(p) 202.420.7612
(c) 703.598.0472
mpolen@aacc.org

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-coronavirus-testing-protocol-could-help-labs-keep-up-with-rising-testing-demands-as-delta-variant-spreads-301338830.html

SOURCE AACC